Sorafenib and Transarterial Chemoembolization for Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
Hepatocellular carcinoma (HCC) as the third most common cause of cancer-related death has a
very poor prognosis. Aim of this open label single arm non randomized pilot trial is the
evaluation of the efficacy and safety of sorafenib in combination with TACE in patients with
unresectable HCC. Efficacy ad safety will be compared with a historical TACE-only group of a
placebo controlled TACE-trial.